US-based Edwards Lifesciences has received CE Mark approval for its Acumen Hypotension Probability Indicator (HPI), which is developed to alert clinicians to potential hypotension, or abnormally low-blood pressure while a patient undergoes surgical and critical care.

Compatible on Edwards' minimally invasive and hemodynamic monitoring solutions, the HPI is comprised of a hypotension probability parameter which is instrumental in indicating hypotensive occurrences using machine learning techniques developed from more than 20,000 past patient events.

An alarm, fitted into the system, warns clinicians when hypotension probability exceeds the limit and a secondary screen visually connects blood pressure to hemodynamic flow parameters, such as cardiac output and contractility.

"An alarm, fitted into the system, warns clinicians when hypotension probability exceeds the limit."

HPI is part of Edwards Acumen decision-support software suite and is run by the minimally invasive FloTrac IQ sensor, within the IQ family of hemodynamic solutions.

Edwards corporate critical care vice-president Catherine Szyman said: "European commercial release of the Acumen Hypotension Probability Indicator builds on a strong foundation of innovation and provides clinicians with the insights to help them make decisions earlier.”

The company is planning to commercially launch HPI in Europe this year and a worldwide launch slated next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.